PE20141067A1 - Compuestos para el tratamiento de la adiccion - Google Patents
Compuestos para el tratamiento de la adiccionInfo
- Publication number
- PE20141067A1 PE20141067A1 PE2013002811A PE2013002811A PE20141067A1 PE 20141067 A1 PE20141067 A1 PE 20141067A1 PE 2013002811 A PE2013002811 A PE 2013002811A PE 2013002811 A PE2013002811 A PE 2013002811A PE 20141067 A1 PE20141067 A1 PE 20141067A1
- Authority
- PE
- Peru
- Prior art keywords
- optionally substituted
- compounds
- alkyl
- treatment
- benzamide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/58—Pyridine rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161503923P | 2011-07-01 | 2011-07-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20141067A1 true PE20141067A1 (es) | 2014-09-05 |
Family
ID=46513858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2013002811A PE20141067A1 (es) | 2011-07-01 | 2012-06-29 | Compuestos para el tratamiento de la adiccion |
Country Status (32)
| Country | Link |
|---|---|
| US (6) | US8558001B2 (OSRAM) |
| EP (2) | EP2993170B1 (OSRAM) |
| JP (1) | JP5943998B2 (OSRAM) |
| KR (2) | KR20160106207A (OSRAM) |
| CN (1) | CN103635460B (OSRAM) |
| AP (1) | AP3544A (OSRAM) |
| AR (1) | AR086792A1 (OSRAM) |
| AU (1) | AU2012279332B2 (OSRAM) |
| BR (1) | BR112014000033A2 (OSRAM) |
| CA (1) | CA2840763C (OSRAM) |
| CL (1) | CL2013003597A1 (OSRAM) |
| CO (1) | CO6821964A2 (OSRAM) |
| CR (1) | CR20130659A (OSRAM) |
| DK (1) | DK2993170T3 (OSRAM) |
| EA (1) | EA025573B1 (OSRAM) |
| EC (1) | ECSP13013087A (OSRAM) |
| ES (2) | ES2656716T3 (OSRAM) |
| IL (1) | IL230657B (OSRAM) |
| MA (1) | MA35404B1 (OSRAM) |
| MD (1) | MD4436B1 (OSRAM) |
| MX (1) | MX337611B (OSRAM) |
| PE (1) | PE20141067A1 (OSRAM) |
| PH (1) | PH12013502674A1 (OSRAM) |
| PL (1) | PL2726460T3 (OSRAM) |
| PT (1) | PT2726460E (OSRAM) |
| SG (1) | SG10201605355RA (OSRAM) |
| SI (1) | SI2726460T1 (OSRAM) |
| TW (1) | TWI567061B (OSRAM) |
| UA (1) | UA109199C2 (OSRAM) |
| UY (1) | UY34165A (OSRAM) |
| WO (1) | WO2013006400A1 (OSRAM) |
| ZA (1) | ZA201308977B (OSRAM) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10457659B2 (en) | 2011-04-29 | 2019-10-29 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for increasing proliferation of adult salivary stem cells |
| TWI577670B (zh) | 2011-05-10 | 2017-04-11 | 基利科學股份有限公司 | 充當離子通道調節劑之稠合雜環化合物 |
| NO3175985T3 (OSRAM) | 2011-07-01 | 2018-04-28 | ||
| TWI478908B (zh) | 2011-07-01 | 2015-04-01 | Gilead Sciences Inc | 作為離子通道調節劑之稠合雜環化合物 |
| TWI567061B (zh) | 2011-07-01 | 2017-01-21 | 吉李德科學股份有限公司 | 用於治療成癮之化合物 |
| CN105358531B (zh) * | 2013-03-14 | 2017-11-14 | 利兰-斯坦福大学初级学院的董事会 | 线粒体醛脱氢酶‑2调节剂和其使用方法 |
| TWI703154B (zh) * | 2013-12-13 | 2020-09-01 | 美商維泰克斯製藥公司 | 作為鈉通道調節劑之吡啶酮醯胺之前藥 |
| US10077669B2 (en) | 2014-11-26 | 2018-09-18 | United Technologies Corporation | Non-metallic engine case inlet compression seal for a gas turbine engine |
| US10289971B2 (en) | 2015-02-13 | 2019-05-14 | Atlassian Pty Ltd | Issue and trigger rebalancing in a ranked issue management system |
| AU2017313390A1 (en) * | 2016-08-19 | 2019-03-07 | The University Of Bristol | Cytisine derivatives for the treatment of addiction |
| JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
| CN111225668A (zh) * | 2017-10-16 | 2020-06-02 | 杏仁体神经科学公司 | 预防成瘾的组合疗法 |
| CN111712494A (zh) | 2018-02-13 | 2020-09-25 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
| EP4600247A3 (en) | 2018-04-19 | 2025-11-19 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| CN112118845B (zh) | 2018-05-14 | 2023-06-13 | 吉利德科学公司 | Mcl-1抑制剂 |
| KR20230159715A (ko) | 2018-07-13 | 2023-11-21 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| WO2020023792A1 (en) * | 2018-07-27 | 2020-01-30 | Amygdala Neurosciences, Inc. | Combination therapy for nicotine addiction |
| WO2020076974A1 (en) * | 2018-10-12 | 2020-04-16 | Amygdala Neurosciences, Inc. | Addiction treatment of an alcohol-consuming patient population |
| AU2019366355B2 (en) | 2018-10-24 | 2022-10-13 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| US12029718B2 (en) | 2021-11-09 | 2024-07-09 | Cct Sciences, Llc | Process for production of essentially pure delta-9-tetrahydrocannabinol |
| US12018009B2 (en) | 2022-06-14 | 2024-06-25 | Amygdala Neurosciences, Inc. | ALDH-2 inhibitor compounds and methods of use |
| EP4540228A1 (en) | 2022-06-14 | 2025-04-23 | Amygdala Neurosciences, Inc. | Aldh-2 inhibitor compounds and methods of use |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| US5204369A (en) | 1991-07-01 | 1993-04-20 | The Endowment For Research In Human Biology | Method for the inhibition of aldh-i useful in the treatment of alcohol dependence or alcohol abuse |
| WO1999058124A1 (en) * | 1998-05-12 | 1999-11-18 | The Endowment For Research In Human Biology, Inc. | Methods and assays useful in the treatment of alcohol dependence or alcohol abuse |
| MXPA05000122A (es) | 2002-06-27 | 2005-12-14 | Endowment For Res In Human Bio | Compuestos utiles para la inhibicion de aldehido-deshidrogenasa. |
| JP2004182657A (ja) * | 2002-12-04 | 2004-07-02 | Eisai Co Ltd | Ｈｄｌレベル上昇促進剤 |
| US20080004260A1 (en) * | 2006-06-29 | 2008-01-03 | Transcept Pharmaceuticals, Inc. | Compositions of 5-HT3 antagonists and dopamine D2 antagonists for treatment of dopamine-associated chronic conditions |
| US8158810B2 (en) | 2006-07-27 | 2012-04-17 | Gilead Sciences, Inc. | ALDH-2 inhibitors in the treatment of addiction |
| US20080207610A1 (en) | 2006-07-27 | 2008-08-28 | Jeff Zablocki | Aldh-2 inhibitors in the treatment of addiction |
| AU2007278877A1 (en) | 2006-07-27 | 2008-01-31 | Gilead Palo Alto, Inc. | ALDH-2 inhibitors in the treatment of addiction |
| US20110105602A2 (en) | 2007-03-08 | 2011-05-05 | Daria Mochly-Rosen | Mitochondrial Aldehyde Dehydrogenase-2 Modulators and Methods of Use Thereof |
| CN101925590A (zh) | 2008-01-24 | 2010-12-22 | 吉利德帕洛阿尔托股份有限公司 | 治疗成瘾的aldh-2抑制剂 |
| PL2300461T3 (pl) | 2008-05-01 | 2013-09-30 | Vitae Pharmaceuticals Inc | Cykliczne inhibitory dehydrogenazy 11beta-hydroksysteroidów 1 |
| CN102209541B (zh) | 2008-09-08 | 2016-05-18 | 小利兰·斯坦福大学托管委员会 | 醛脱氢酶活性调节剂和其使用方法 |
| CN102202669A (zh) * | 2008-10-28 | 2011-09-28 | 利兰·斯坦福青年大学托管委员会 | 醛脱氢酶调节剂及其使用方法 |
| UY33469A (es) * | 2010-06-29 | 2012-01-31 | Irm Llc Y Novartis Ag | Composiciones y metodos para modular la via de señalizacion de wnt |
| TWI567061B (zh) * | 2011-07-01 | 2017-01-21 | 吉李德科學股份有限公司 | 用於治療成癮之化合物 |
-
2012
- 2012-06-26 TW TW101122794A patent/TWI567061B/zh not_active IP Right Cessation
- 2012-06-27 UY UY0001034165A patent/UY34165A/es not_active Application Discontinuation
- 2012-06-28 AR ARP120102331A patent/AR086792A1/es not_active Application Discontinuation
- 2012-06-29 PE PE2013002811A patent/PE20141067A1/es not_active Application Discontinuation
- 2012-06-29 UA UAA201314148A patent/UA109199C2/ru unknown
- 2012-06-29 AU AU2012279332A patent/AU2012279332B2/en not_active Ceased
- 2012-06-29 ES ES15184883.5T patent/ES2656716T3/es active Active
- 2012-06-29 WO PCT/US2012/044809 patent/WO2013006400A1/en not_active Ceased
- 2012-06-29 SI SI201230340T patent/SI2726460T1/sl unknown
- 2012-06-29 KR KR1020167023967A patent/KR20160106207A/ko not_active Withdrawn
- 2012-06-29 EP EP15184883.5A patent/EP2993170B1/en active Active
- 2012-06-29 JP JP2014519122A patent/JP5943998B2/ja not_active Expired - Fee Related
- 2012-06-29 KR KR1020147002302A patent/KR101664915B1/ko not_active Expired - Fee Related
- 2012-06-29 CN CN201280032944.6A patent/CN103635460B/zh not_active Expired - Fee Related
- 2012-06-29 PL PL12735394T patent/PL2726460T3/pl unknown
- 2012-06-29 DK DK15184883.5T patent/DK2993170T3/da active
- 2012-06-29 MD MDA20140009A patent/MD4436B1/ro not_active IP Right Cessation
- 2012-06-29 PT PT127353944T patent/PT2726460E/pt unknown
- 2012-06-29 PH PH1/2013/502674A patent/PH12013502674A1/en unknown
- 2012-06-29 CA CA2840763A patent/CA2840763C/en active Active
- 2012-06-29 EA EA201391635A patent/EA025573B1/ru not_active IP Right Cessation
- 2012-06-29 EP EP12735394.4A patent/EP2726460B1/en active Active
- 2012-06-29 AP AP2013007282A patent/AP3544A/xx active
- 2012-06-29 BR BR112014000033A patent/BR112014000033A2/pt active Search and Examination
- 2012-06-29 US US13/537,536 patent/US8558001B2/en active Active
- 2012-06-29 ES ES12735394.4T patent/ES2553829T3/es active Active
- 2012-06-29 SG SG10201605355RA patent/SG10201605355RA/en unknown
- 2012-06-29 MX MX2013014938A patent/MX337611B/es active IP Right Grant
-
2013
- 2013-03-08 US US13/791,422 patent/US8575353B2/en active Active
- 2013-08-13 US US13/966,029 patent/US9000015B2/en active Active
- 2013-11-28 ZA ZA2013/08977A patent/ZA201308977B/en unknown
- 2013-12-13 CR CR20130659A patent/CR20130659A/es unknown
- 2013-12-16 CL CL2013003597A patent/CL2013003597A1/es unknown
- 2013-12-18 CO CO13295408A patent/CO6821964A2/es active IP Right Grant
- 2013-12-18 EC ECSP13013087 patent/ECSP13013087A/es unknown
- 2013-12-30 MA MA36629A patent/MA35404B1/fr unknown
-
2014
- 2014-01-26 IL IL230657A patent/IL230657B/en active IP Right Grant
-
2015
- 2015-03-16 US US14/659,042 patent/US9610299B2/en not_active Expired - Fee Related
-
2017
- 2017-03-31 US US15/476,569 patent/US9987295B2/en active Active
-
2018
- 2018-05-08 US US15/974,171 patent/US10507215B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20141067A1 (es) | Compuestos para el tratamiento de la adiccion | |
| PE20161416A1 (es) | Derivados de benzamida para la inhibicion de la actividad abl1, abl2 y bcr-abl1 | |
| PE20170331A1 (es) | Derivados quinolina como inhibidores smo | |
| PE20141064A1 (es) | Compuestos de ester boronato y composciones farmaceuticas de los mismos | |
| PE20161218A1 (es) | (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1 | |
| BR112014015363A2 (pt) | derivados de ácido alfa-amino borônico, inibidores de imunoproteassoma seletivos | |
| PE20170004A1 (es) | Inhibidores de biaril cinasa | |
| AR072490A1 (es) | 1,2,5- oxadiazoles como inhibidores de indolamina 2,3 dioxigenasa | |
| PE20151602A1 (es) | SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD AGONISTA DEL RECEPTOR B(beta)2 ADRENERGICO ASI COMO ACTIVIDAD ANTAGONISTA DEL RECEPTOR MUSCARINICO M3 | |
| PE20140934A1 (es) | Derivados de pirazol | |
| AR057109A1 (es) | Benzimidazoles sustituidos y metodos para usarlos como inhibidores de las quinasas asociadas con la tumorigenesis | |
| CU20110217A7 (es) | Derivados amino-propiónicos sustituidos como inhibidores de neprilisina | |
| PE20120171A1 (es) | Sales de adicion de aminas que contienen grupos hidroxilo y/o carboxilicos con derivados de acidos aminonicotinico como inhibidores de dhodh | |
| PE20091002A1 (es) | Analogos dipeptidos como inhibidores del factor de coagulacion | |
| PE20160863A1 (es) | Proceso para la sintesis de un inhibidor de indolamina 2,3-dioxigenasa | |
| RU2014149183A (ru) | Проницаемые ингибиторы гликозидазы и их применения | |
| AR087995A1 (es) | Derivados de n-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-n-(4-fluorofenil)ciclopropan-1,1-dicarboxamida | |
| AR084144A1 (es) | Compuestos y metodos para restaurar la piel | |
| PE20150224A1 (es) | Inhibidores del nampt | |
| PE20151666A1 (es) | Derivados sustituidos del acido bisfenil butanoico fosfonico como inhibidores de la nep | |
| BR112013029999A2 (pt) | derivados de tiazol | |
| PE20141679A1 (es) | Derivados de bencil sulfonamida utiles como inhibidores de mogat-2 | |
| EA201300436A8 (ru) | Совместные кристаллы и соли ингибиторов ccr3 | |
| EA201391524A1 (ru) | Производные гликозида и их применение | |
| PE20140629A1 (es) | Derivados de fenil-isoxazol y procedimiento para la preparacion de los mismos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |